P2RY12 and atrial fibrillation: Thus, researchers have focused on the antithrombotic activation and effect of preventing cardiovascular events of DABE in conjunction with ticagrelor22,23, reaching conclusions that a triple therapy of DABE in combination with ticagrelor plus aspirin is as effective as warfarin triple regimen22, and dual therapy of DABE plus a P2Y12 inhibitor (clopidogrel or ticagrelor) is non-inferior to triple therapy of warfarin plus a P2Y12 inhibitor (clopidogrel or ticagrelor) and aspirin among patients with atrial fibrillation after PCI, and the risk of bleeding is lower23.